艾利利利的新药"穆瓦拉普林"显著降低有害的胆固醇变体. New Eli Lilly drug muvalaplin shows promise in significantly reducing harmful cholesterol variant.

在最近的一项研究中,一种新的口服药物 -- -- muvalaplin -- -- 在降低与心脏病相关联的胆固醇变异物 -- -- 脂蛋白(a)水平方面显示出重大前景。 A new oral drug, muvalaplin, has shown significant promise in reducing levels of lipoprotein(a), a cholesterol variant linked to heart disease, in a recent study. 该药物由Eli Lilly研制,在12周内用三剂进行测试,并成功地将脂质蛋白(a)水平降低了85.8%的参与者。 Developed by Eli Lilly, the drug was tested at three doses over 12 weeks and managed to lower lipoprotein(a) levels by up to 85.8% in participants. 由于目前没有经批准的治疗方法,如果进一步试验证实其有效性和安全性,马瓦拉普林就可能成为改变游戏的改变者。 With no approved treatments currently available, muvalaplin could be a game-changer if further trials confirm its effectiveness and safety.

文章

Market Screener

Medical Xpress

HCPLive

American Journal of Managed Care

JAMA Network

-- 显示更少 --

相关故事